The cluster initial mass function of the M82 disk Super Star Clusters

The presence of a population of a large number ($\sim$400) of almost coeval (100--300 Myr) super star clusters (SSCs) in the disk of M82 offers an opportunity to construct the Cluster Initial Mass Function (CIMF) from the observed present-day Cluster Mass Function (CMF). We carry out the dynamical and photometric evolution of the CMF assuming the clusters move in circular orbits under the gravitational potential of the host galaxy using the semi-analytical simulation code EMACSS. We explore power-law and log-normal functions for the CIMFs, and populate the clusters in the disk assuming uniform, power-law, and exponential radial distribution functions. We find that the observed CMF is best produced by a CIMF that is power-law in form with an index of 1.8, for a power-law radial distribution function. More importantly, we establish that the observed turn-over in the present-day CMF is the result of observational incompleteness rather than due to dynamically induced effects, or an intrinsically log-normal CIMF, as was proposed for the fossil starburst region B of this galaxy. Our simulations naturally reproduce the mass-radius relation observed for a sub-sample of M82 SSCs.Comment: 17 pages, 11 figures, accepted to be published on MNRA

Realidades interculturales, miradas hacia el género y la educación

Este texto contribuye al análisis científico de varias áreas del conocimiento como la filosofía social, la patología, la educación para el cuidado del medio ambiente y la sustentabilidad que inciden en diversas unidades de aprendizaje de la Licenciatura en Educación para la Salud y de la Maestría en Sociología de la SaludLa presente obra, es la reunión de varias investigaciones que se han dado cita para construir un libro que representa el horizonte de autores y lectores en la pasión del dialogo. Se trata de experiencias de los observadores e interpretes de la realidad de los observadores e interpretes de la realidad social quienes se aventuraron a reunir las voces de los informantes que resguardan los secretos de sus comunidades acerca de su cultura, organización simbólica, y de sus practicas y rituales engarzados en la vida cotidiana

REALIDADES INTERCULTURALES

EL LIBRO FOMENTA LA LÍNEA DE INVESTIGACIÓN DEL CUERPO ACADÉMICO DE GÉNERO, SUSTENTABILIDAD, EDUCACIÓN Y SALUDSE RETOMAN EXPERIENCIAS DE LOS INTERPRETES DE LA REALIDAD SOCIAL QUIENES GUARDAN LOS SECRETOS DE SUS COMUNIDADES ACERCA DE LA CULTURA, ORGANIZACIÓN SIMBÓLICA DE LA VIDA COTIDIANANINGUNO ES PERSONA

Estudios de Caso sobre Ciencias Agropecuarias y Rurales en el siglo XXI.

Libro científico sobre estudios de casos en el medio agropecuario y ruralCon el advenimiento del siglo XXI y el avance de los procesos de globalización, el medio rural presenta diversos cambios económicos, sociales, políticos y culturales. Lo anterior significa que el campo es un objeto de estudio altamente dinámico, complejo e inasible. las ciencias agropecuarias y rurales, en la actualidad, requieren de un abordaje sistémico e interdisciplinario que den cuenta de la heterogeneidad de situaciones y contextos que enfrenta el campo mexicano. La presente obra agrupa 18 estudios de caso, que capturan algunas fotografías de las diversas problemáticas de la ruralidad mexicana, con lo cual se pretende dar cuenta tanto de los objetivos de estudio como de la perspectiva teórico metodológico desde que estos son abordados. lo anterior tiene que ver con el hecho de que las ciencias agropecuarias y rurales manifiestan un alto grado de observación empírica, motivo por el que los estudios de caso se convierten en la perspectiva metodológica idónea que permite ir y venir de la realidad a la teoría y viceversa para la construcción de objetos de estudio. En este volumen se aborda una gran diversidad de casos, que sintetizan la heterogeneidad de enfoques y perspectivas mediante las cuales los fenómenos agropecuarios y rurales han sido abordados en el Instituto de Ciencias Agropecuarias y Rurales de la Universidad Autónoma del Estado de México, en los últimos 30 años

Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

Background: Approximately 450 000 children are born with familial hypercholesterolaemia worldwide every year, yet only 2·1% of adults with familial hypercholesterolaemia were diagnosed before age 18 years via current diagnostic approaches, which are derived from observations in adults. We aimed to characterise children and adolescents with heterozygous familial hypercholesterolaemia (HeFH) and understand current approaches to the identification and management of familial hypercholesterolaemia to inform future public health strategies. Methods: For this cross-sectional study, we assessed children and adolescents younger than 18 years with a clinical or genetic diagnosis of HeFH at the time of entry into the Familial Hypercholesterolaemia Studies Collaboration (FHSC) registry between Oct 1, 2015, and Jan 31, 2021. Data in the registry were collected from 55 regional or national registries in 48 countries. Diagnoses relying on self-reported history of familial hypercholesterolaemia and suspected secondary hypercholesterolaemia were excluded from the registry; people with untreated LDL cholesterol (LDL-C) of at least 13·0 mmol/L were excluded from this study. Data were assessed overall and by WHO region, World Bank country income status, age, diagnostic criteria, and index-case status. The main outcome of this study was to assess current identification and management of children and adolescents with familial hypercholesterolaemia. Findings: Of 63 093 individuals in the FHSC registry, 11 848 (18·8%) were children or adolescents younger than 18 years with HeFH and were included in this study; 5756 (50·2%) of 11 476 included individuals were female and 5720 (49·8%) were male. Sex data were missing for 372 (3·1%) of 11 848 individuals. Median age at registry entry was 9·6 years (IQR 5·8-13·2). 10 099 (89·9%) of 11 235 included individuals had a final genetically confirmed diagnosis of familial hypercholesterolaemia and 1136 (10·1%) had a clinical diagnosis. Genetically confirmed diagnosis data or clinical diagnosis data were missing for 613 (5·2%) of 11 848 individuals. Genetic diagnosis was more common in children and adolescents from high-income countries (9427 [92·4%] of 10 202) than in children and adolescents from non-high-income countries (199 [48·0%] of 415). 3414 (31·6%) of 10 804 children or adolescents were index cases. Familial-hypercholesterolaemia-related physical signs, cardiovascular risk factors, and cardiovascular disease were uncommon, but were more common in non-high-income countries. 7557 (72·4%) of 10 428 included children or adolescents were not taking lipid-lowering medication (LLM) and had a median LDL-C of 5·00 mmol/L (IQR 4·05-6·08). Compared with genetic diagnosis, the use of unadapted clinical criteria intended for use in adults and reliant on more extreme phenotypes could result in 50-75% of children and adolescents with familial hypercholesterolaemia not being identified. Interpretation: Clinical characteristics observed in adults with familial hypercholesterolaemia are uncommon in children and adolescents with familial hypercholesterolaemia, hence detection in this age group relies on measurement of LDL-C and genetic confirmation. Where genetic testing is unavailable, increased availability and use of LDL-C measurements in the first few years of life could help reduce the current gap between prevalence and detection, enabling increased use of combination LLM to reach recommended LDL-C targets early in life

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

Background: The EMPA KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. Methods: EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110. Findings: Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5–2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62–0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16–1·59), representing a 50% (42–58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all >0·1). Interpretation: In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease. Funding: Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council

Simulated LCSLM with Inducible Diffractive Theory to Display Super-Gaussian Arrays Applying the Transport-of-Intensity Equation

We simulate a liquid crystal spatial light modulator (LCSLM), previously validated by Fraunhofer diffraction to observe super-Gaussian periodic profiles and analyze the wavefront of optical surfaces applying the transport-of-intensity equation (TIE). The LCSLM represents an alternative to the Ronchi Rulings, allowing to avoid all the related issues regarding diffractive and refractive properties, and noise. To this aim, we developed and numerically simulated a LCSLM resembling a fractal from a generating base. Such a base is constituted by an active square (values equal to one) and surrounded by eight switched-off pixels (zero-valued). We replicate the base in order to form 1 ×N-pixels and the successive rows to build the 1024×1024 LCSLM of active pixels. We visually test the LCSLM with calibration images as a diffractive object that is mathematically inducible, using mathematical induction over the N×N-shape (1×1, 2×2, 3×3, …, n×n pixels for the generalization). Finally, we experimentally generate periodic super-Gaussian profiles to be visualized in the LCSLM (transmission SLM, 1024×768-pixels LC 2012 Translucent SLM), modifying the TIE as an optical test in order to analyze the optical elements by comparing the results with ZYGO/APEX

Calificación, Valorización y Turismo. Aproximaciones al patrimonio agroalimentario

Libro científico sobre los espacios rurales y sus procesos de revalorización y resignificación en el siglo XXI.A partir de la segunda mitad del siglo XXI, los espacios rurales han transformado su estructura y funcionalidad de cara a las sociedades de consumo de la economía postindustrial. Al respecto, se ha generado un proceso de revalorización y resignificación del espacio rural que se centra en la atención sobre sus aspectos sociales, culturales, ecológicos, económicos y recreativos. En ese sentido, puede observarse la emergencia de algunas prácticas trasversales que se presentan como tendencias globales de la planificación, política y económica, de los espacios rurales y el aprovechamientos recreativos del capital natural y cultural del campo. La presente obra constituye un compendio de estudios de caso sobre los procesos de calificación, valorización y turistificación de ciertos recursos locales diferenciados, característicos del altiplano central mexicano. En este primer volumen se abordan los procesos de valorización y diversificación productiva de los recursos rurales, desde el enfoque turístico metodológico de los Sistemas Agroalimentarios Localizados (SIAL). Este es un trabajo colectivo que refleja los esfuerzos invertidos en los procesos de trasformación socioeconómica del espacio rural, gestados desde la Maestría en Agroindustria Rural, Desarrollo Territorial y Turismo Agroalimentario, de la Universidad Autónoma del Estado de México

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo

Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF

BACKGROUND: Many patients with atrial fibrillation have concomitant coronary artery disease with or without acute coronary syndromes and are in need of additional antithrombotic therapy. There are few data on the long-term clinical outcome of atrial fibrillation patients with a history of acute coronary syndrome. This is a 2-year study of atrial fibrillation patients with or without a history of acute coronary syndromes